Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

Adherence and patients’ experiences with the use of oral anticancer agents

(2013) Lonneke Timmers et al.   ACTA ONCOLOGICA

Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review

(2013) M. Verbrugghe et al.   CANCER TREATMENT REVIEWS

Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer

(2013) Vittorio Gebbia et al.   Clinical Lung Cancer

Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

(2013) J.R. Brahmer et al.   EUROPEAN JOURNAL OF CANCER

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

(2013) Marina Chiara Garassino et al.   LANCET ONCOLOGY

An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib

(2013) J.F. Hilton et al.   LUNG CANCER

Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials

(2012) Fausto Petrelli et al.   Clinical Lung Cancer

Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer

(2012) Raffaele Califano et al.   DRUGS

Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology

(2012) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)

(2012) Jacques Cadranel et al.   Journal of Thoracic Oncology

Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials

(2012) Fausto Petrelli et al.   LUNG CANCER

The use of erlotinib in daily practice: a study on adherence and patients' experiences

(2011) Lonneke Timmers et al.   BMC CANCER

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

(2011) A C Mita et al.   BRITISH JOURNAL OF CANCER

Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

(2011) Wolfram Brugger et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104

(2010) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

The Missing Voice of Patients in Drug-Safety Reporting

(2010) Ethan Basch   NEW ENGLAND JOURNAL OF MEDICINE

Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals

(2009) Jie Ling et al.   ANTI-CANCER DRUGS

Patient adherence and persistence with oral anticancer treatment

(2009) K. Ruddy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

(2009) Fabienne Thomas et al.   EUROPEAN JOURNAL OF CANCER

Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes

(2009) Ethan Basch et al.   JNCI-Journal of the National Cancer Institute

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY